Brayer et al., 2015 - Google Patents
WT 1 vaccination in AML and MDS: A pilot trial with synthetic analog peptidesBrayer et al., 2015
View PDF- Document ID
- 5665577916574917028
- Author
- Brayer J
- Lancet J
- Powers J
- List A
- Balducci L
- Komrokji R
- Pinilla‐Ibarz J
- Publication year
- Publication venue
- American journal of hematology
External Links
Snippet
Peptide vaccines are capable of eliciting immune responses targeting tumor‐associated antigens such as the Wilms' Tumor 1 (WT1) antigen, often overexpressed in myeloid malignancies. Here, we assessed the safety, tolerability, and immunogenicity of a polyvalent …
- 206010000880 Acute myeloid leukaemia 0 title abstract description 62
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brayer et al. | WT 1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides | |
| Tanyi et al. | Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer | |
| Khoury et al. | Immune responses and long‐term disease recurrence status after telomerase‐based dendritic cell immunotherapy in patients with acute myeloid leukemia | |
| Bhardwaj et al. | Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets | |
| Fourcade et al. | Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients | |
| Mielgo-Rubio et al. | Immunotherapy in non-small cell lung cancer: Update and new insights | |
| Brennick et al. | Neoepitopes as cancer immunotherapy targets: key challenges and opportunities | |
| Prins et al. | Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy | |
| Weber et al. | White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy | |
| Schuhmacher et al. | Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial | |
| Mellman et al. | Cancer immunotherapy comes of age | |
| Le et al. | Cellular vaccine approaches | |
| Voskens et al. | Induction of MAGE‐A3 and HPV‐16 immunity by Trojan vaccines in patients with head and neck carcinoma | |
| Tiriveedhi et al. | Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer | |
| Martin Lluesma et al. | Cancer vaccines in ovarian cancer: how can we improve? | |
| JP2021178854A (en) | Vaccines for treatment and prevention of cancer | |
| Yuan et al. | Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma | |
| Zhang et al. | Cancer vaccines: Targeting KRAS-driven cancers | |
| Obara et al. | Phase I clinical trial of cell division associated 1 (CDCA 1) peptide vaccination for castration resistant prostate cancer | |
| Patel et al. | Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial | |
| EP3601536A1 (en) | Treatment methods | |
| Lichtenegger et al. | Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial | |
| Bilusic et al. | Therapeutic cancer vaccines: the latest advancement in targeted therapy | |
| Yanagimoto et al. | Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer | |
| Sweis et al. | Emerging role of immunotherapy in urothelial carcinoma—Immunobiology/biomarkers |